How This Evidence Evolved
Adult ADHD Recognition and Treatment
Recognition, validation, and treatment of attention-deficit/hyperactivity disorder across the adult lifespan
Timeline
Early observations and pilot data that first suggested a new direction
Current prevalence of adult ADHD
Remission by age, 3 definitions, 128 boys, 4 years
ADHD persistence at age 25: full criteria only vs including DSM-IV partial remission (about 15% vs about 65%)
Landmark RCTs and pivotal trials that established the evidence base
Effect sizes for adult ADHD medication efficacy
ADHD symptom severity, short term (mean 8.1 weeks): amphetamines vs placebo (SMD -0.72, 95% CI -0.87 to -0.57); retention in treatment not improved overall
ADHD symptom severity, short term: stimulants vs placebo (Cohen's d 0.67, p<0.0001); non-stimulants vs placebo (d 0.59, p<0.0001)
Follow-up studies, subgroup analyses, and real-world validation
Serious cardiovascular events (MI, stroke, sudden cardiac death)
ADHD-RS total-score change at 4 weeks: lisdexamfetamine 30/50/70 mg/day −16.2/−17.4/−18.6 vs placebo −8.2 (all P<.0001).
Assessor-rated ADHD rating scale response after treatment: CBT vs relaxation with educational support (67% vs 33%; OR 4.29, 95% CI 1.74-10.58; P=.002)
ADHD prevalence, childhood vs adult (cohort followed to age 38): 6% vs 3%; 90% of adult cases lacked a history of childhood ADHD
ADHD at 11 years vs at 18-19 years: 8.9% vs 12.2%; only 12.6% of young-adult cases had the disorder in childhood
Adult ADHD at age 18: 112 of 166 cases (67.5%) did not meet ADHD criteria at any childhood assessment
Adult ADHD symptoms and functioning: review of short-term and longer-term lisdexamfetamine studies
Adult ADHD symptoms: atomoxetine Hedges g −0.48 (95% CI −0.64 to −0.33); guanfacine −0.66 (−0.94 to −0.38) vs placebo
Current standard of care and ongoing research directions
Adult quality of life and functional impairment compared by ADHD age of onset
Diagnostic accuracy in Korean adult outpatients: 92%; sensitivity 91.30%, specificity 93.62%
Spanish CAADID diagnostic sensitivity 98.86%, specificity 67.68%; clinical-interview concordance kappa 0.88
Landmark Trials in This Story
The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication
Current prevalence of adult ADHD
Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type
Remission by age, 3 definitions, 128 boys, 4 years
The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies.
ADHD persistence at age 25: full criteria only vs including DSM-IV partial remission (about 15% vs about 65%)
A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes
Effect sizes for adult ADHD medication efficacy
Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults.
ADHD symptom severity, short term (mean 8.1 weeks): amphetamines vs placebo (SMD -0.72, 95% CI -0.87 to -0.57); retention in treatment not improved overall
Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.
ADHD symptom severity, short term: stimulants vs placebo (Cohen's d 0.67, p<0.0001); non-stimulants vs placebo (d 0.59, p<0.0001)
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults
Serious cardiovascular events (MI, stroke, sudden cardiac death)
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
ADHD-RS total-score change at 4 weeks: lisdexamfetamine 30/50/70 mg/day −16.2/−17.4/−18.6 vs placebo −8.2 (all P<.0001).
Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial.
Assessor-rated ADHD rating scale response after treatment: CBT vs relaxation with educational support (67% vs 33%; OR 4.29, 95% CI 1.74-10.58; P=.002)
Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence From a Four-Decade Longitudinal Cohort Study.
ADHD prevalence, childhood vs adult (cohort followed to age 38): 6% vs 3%; 90% of adult cases lacked a history of childhood ADHD
Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-Onset Syndrome.
ADHD at 11 years vs at 18-19 years: 8.9% vs 12.2%; only 12.6% of young-adult cases had the disorder in childhood
Evaluation of the Persistence, Remission, and Emergence of Attention-Deficit/Hyperactivity Disorder in Young Adulthood.
Adult ADHD at age 18: 112 of 166 cases (67.5%) did not meet ADHD criteria at any childhood assessment
Lisdexamfetamine: A Review in ADHD in Adults.
Adult ADHD symptoms and functioning: review of short-term and longer-term lisdexamfetamine studies
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Adult ADHD symptoms: atomoxetine Hedges g −0.48 (95% CI −0.64 to −0.33); guanfacine −0.66 (−0.94 to −0.38) vs placebo
Validation of DSM-5 age-of-onset criterion of attention deficit/hyperactivity disorder (ADHD) in adults: Comparison of life quality, functional impairment, and family function.
Adult quality of life and functional impairment compared by ADHD age of onset
Validity of the Korean Version of DIVA-5: A Semi-Structured Diagnostic Interview for Adult ADHD.
Diagnostic accuracy in Korean adult outpatients: 92%; sensitivity 91.30%, specificity 93.62%
Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version.
Spanish CAADID diagnostic sensitivity 98.86%, specificity 67.68%; clinical-interview concordance kappa 0.88
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.